Drug rechallenge and treatment beyond progression—implications for drug resistance
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug rechallenge and treatment beyond progression—implications for drug resistance
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 10, Issue 10, Pages 571-587
Publisher
Springer Nature
Online
2013-09-03
DOI
10.1038/nrclinonc.2013.158
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy
- (2015) Terence C. Tang et al. NEOPLASIA
- Intermittent and continuous imatinib in a human GIST xenograft model carryingKITexon 17 resistance mutation D816H
- (2013) Mona-Elisabeth Revheim et al. ACTA ONCOLOGICA
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma
- (2013) Maria T. Petrucci et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Model of Postsurgical Advanced Metastatic Breast Cancer More Accurately Replicates the Clinical Efficacy of Antiangiogenic Drugs
- (2013) E. Guerin et al. CANCER RESEARCH
- Does T790M Disappear? Successful Gefitinib Rechallenge After T790M Disappearance in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer
- (2013) Akito Hata et al. Journal of Thoracic Oncology
- EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case–control study of overall survival
- (2013) M. Faehling et al. LUNG CANCER
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Transient Sunitinib Resistance in Gastrointestinal Stromal Tumors
- (2013) Raffaella Bracci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial
- (2012) A. Patrikidou et al. ANNALS OF ONCOLOGY
- Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
- (2012) D. Santini et al. ANNALS OF ONCOLOGY
- Sorafenib rechallenge in patients with metastatic renal cell carcinoma
- (2012) Masahiro Nozawa et al. BJU INTERNATIONAL
- Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer
- (2012) Matthias M. Heck et al. BJU INTERNATIONAL
- Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
- (2012) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
- (2012) Man Yu et al. CANCER AND METASTASIS REVIEWS
- A Pooled Analysis of 2618 Patients Treated With Trastuzumab Beyond Progression for Advanced Breast Cancer
- (2012) Fausto Petrelli et al. Clinical Breast Cancer
- Bevacizumab rechallenge after first line maintenance bevacizumab
- (2012) Panagiotis A. Konstantinopoulos et al. GYNECOLOGIC ONCOLOGY
- Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101
- (2012) Lawrence N. Shulman et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
- (2012) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
- (2012) Kenichi Nishie et al. Journal of Thoracic Oncology
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study
- (2012) In-Jae Oh et al. LUNG CANCER
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- Treatment selection in metastatic renal cell carcinoma: expert consensus
- (2012) Bernard Escudier et al. Nature Reviews Clinical Oncology
- Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer
- (2012) A. Kreso et al. SCIENCE
- A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma
- (2012) S. Sivanand et al. Science Translational Medicine
- LGR5-Positive Colon Cancer Stem Cells Interconvert with Drug-Resistant LGR5-Negative cells and are Capable of Tumor Reconstitution
- (2012) Shinta Kobayashi et al. STEM CELLS
- Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients
- (2011) Michael Fiegl et al. ANNALS OF HEMATOLOGY
- Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib
- (2011) Antoine Italiano et al. ANNALS OF SURGICAL ONCOLOGY
- Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
- (2011) Renhua Guo et al. BMC CANCER
- Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study
- (2011) Manuela Campiglio et al. BREAST CANCER RESEARCH AND TREATMENT
- Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions
- (2011) M. Pegram et al. Clinical Breast Cancer
- Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen
- (2011) Lorenzo Fornaro et al. Clinical Colorectal Cancer
- Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
- (2011) A. Becker et al. EUROPEAN JOURNAL OF CANCER
- Response to Imatinib Rechallenge of GIST That Recurs Following Completion of Adjuvant Imatinib Treatment - the First Analysis in the SSGXVIII/AIO Trial Patient Population
- (2011) P. Reichardt et al. EUROPEAN JOURNAL OF CANCER
- Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- (2011) Alessandra Gennari et al. JOURNAL OF CLINICAL ONCOLOGY
- High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
- (2011) Xiaoen Wang et al. Journal of Translational Medicine
- Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Richard A Adams et al. LANCET ONCOLOGY
- Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype
- (2011) K. He et al. MOLECULAR CANCER THERAPEUTICS
- Rechallenge with temozolomide in recurrent glioma
- (2011) P. Gaviani et al. NEUROLOGICAL SCIENCES
- Bending the Cost Curve in Cancer Care
- (2011) Thomas J. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
- (2011) Hajime Asahina et al. ONCOLOGY
- Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland
- (2011) I. Hrusovsky et al. ONCOLOGY
- Reintroduction of Oxaliplatin: A Viable Approach to the Long-Term Management of Metastatic Colorectal Cancer
- (2011) Axel Grothey ONCOLOGY
- Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC
- (2011) Viktor Grünwald et al. ONKOLOGIE
- Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
- (2011) Liang Zhang et al. PLoS One
- Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells
- (2011) Ellen Weisberg et al. PLoS One
- Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
- (2011) J. Chmielecki et al. Science Translational Medicine
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
- (2010) Jean-Christophe Eymard et al. BJU INTERNATIONAL
- Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
- (2010) Giuseppe Di Lorenzo et al. BJU INTERNATIONAL
- Sunitinib rechallenge in metastatic renal cell carcinoma patients
- (2010) Ivan N. Zama et al. CANCER
- Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized
- (2010) Elsa Quintana et al. CANCER CELL
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts
- (2010) Mothaffar F. Rimawi et al. CLINICAL CANCER RESEARCH
- Chemotherapy Resistance and Retreatment: A Dogma Revisited
- (2010) Aung Naing et al. Clinical Colorectal Cancer
- The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
- (2010) Yohann Loriot et al. EUROPEAN JOURNAL OF CANCER
- The therapeutic promise of the cancer stem cell concept
- (2010) Natasha Y. Frank et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
- (2010) James R. Perry et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
- (2010) Axel Le Cesne et al. LANCET ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
- (2010) H. J. Hammers et al. MOLECULAR CANCER THERAPEUTICS
- Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
- (2010) Kae Hashimoto et al. MOLECULAR CANCER THERAPEUTICS
- Diverse somatic mutation patterns and pathway alterations in human cancers
- (2010) Zhengyan Kan et al. NATURE
- Rechallenging with anthracyclines and taxanes in metastatic breast cancer
- (2010) Carlo Palmieri et al. Nature Reviews Clinical Oncology
- Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
- (2010) J.-M. Extra et al. ONCOLOGIST
- Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment
- (2010) Marcus Alexander Wörns et al. ONCOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
- (2009) Benoist Chibaudel et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Rechallenge with temozolomide in patients with recurrent gliomas
- (2009) Antje Wick et al. JOURNAL OF NEUROLOGY
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
- (2009) T. Fojo et al. JNCI-Journal of the National Cancer Institute
- Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy
- (2009) Hyun-Gyung Goh et al. LEUKEMIA & LYMPHOMA
- Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
- (2009) Yoshio Tomizawa et al. LUNG CANCER
- Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells
- (2009) C. Morales et al. MOLECULAR CANCER THERAPEUTICS
- Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment
- (2008) D. H. Lee et al. ANNALS OF ONCOLOGY
- Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy
- (2008) R A Cox et al. BRITISH JOURNAL OF CANCER
- A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer
- (2008) J Shamash et al. BRITISH JOURNAL OF CANCER
- Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule
- (2008) James R. Perry et al. CANCER
- Stopping Treatment Can Reverse Acquired Resistance to Letrozole
- (2008) G. J. Sabnis et al. CANCER RESEARCH
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial
- (2008) S. Leyvraz et al. JNCI-Journal of the National Cancer Institute
- Lung Cancer Response to Gefitinib, Then Erlotinib, Then Gefitinib Again
- (2008) Alvin S. Wong et al. Journal of Thoracic Oncology
- Dynamic Proteomics of Individual Cancer Cells in Response to a Drug
- (2008) A. A. Cohen et al. SCIENCE
- Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
- (2008) Bostjan Seruga et al. Nature clinical practice. Oncology
- Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer
- (2007) Tomasz M. Beer et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started